Iksuda Therapeutics presents first data on lead antibody drug conjugate, demonstrating effective tumour regression September 30, 2019 2019
Glythera Announces Corporate Name Change and Rebranding to Iksuda Therapeutics September 10, 2018 2018
Positive Outcome of Proof-of-Concept Study with Glythera and Follow on Drug Development Partnership January 15, 2018 2018
Glythera licenses novel payload class from Cancer Research UK for the development of next-generation antibody drug conjugates September 26, 2017 Library
